

Supplementary Materials

# The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population

Chloe E. Barr, Garth Funston, David Jeevan, Sudha Sundar, Luke T. A. Mounce and Emma J. Crosbie

**Table S1.** Malignancies diagnosed within 12 months of index CA125 test in primary care group.

ID no ( <i>n</i> = 17)	Tumour Site	Histological subtype	Grade	Stage	CA125 ≥ 35 U/mL	HE4 ≥ 77 pmol/L
3	Breast	Invasive ductal	2	T2, N0, M0	No	No
254	Breast	Mixed invasive lobular and ductal	2	Lobular- T2, N0, M0 Ductal- T1, N0, M0	No	No
459	Colorectal	Adenocarcinoma	2	T4, N0, M0	No	No
29	Colorectal	Adenocarcinoma	2	T3, N0, M0	Yes	Yes
996	Colorectal	Adenocarcinoma	3	T4a, N2b, M0	Yes	No
1130	Colorectal	Adenocarcinoma	2	T3, N0, M0	No	Yes
455	Lung	Non-small cell	NK	T1C, N0, M0	No	Yes
696	Lung	Non-small cell	NK	T1A, N0, M0	No	Yes
1010	Lung	Non-small cell	NK	T1c, N0, M0	No	Yes
64	Endometrial	Endometrioid	1	1A	No	No
580	Endometrial	Endometrioid	3	1B	Yes	Yes
1214	Endometrial	Endometrioid	1	1A	No	Yes
436	Ovarian	Borderline serous	NA	1C	Yes	No
542	Ovarian	Serous	3	4B	Yes	Yes
967	Renal	Transitional cell carcinoma	NK	T4b, N2, M0	No	Yes
1081	Unknown Primary	Adenocarcinoma	3	4B	Yes	Yes
1221	Lymphoma	Extra nodal marginal zone	NK	NK	No	Yes

n- number. NK- not known

**Table S2.** Clinico-demographics of the cohort referred to hospital for investigation with a raised serum HE4 (*n* = 101).

Clinico- demographic variable	Number (%)
<b>Age (years)</b>	
Median (IQR)	61.5 (51–75)
<b>BMI (kg/m<sup>2</sup>)</b>	
Median (IQR)	26 (23–31)
<b>Ethnicity</b>	
White	74 (73.3)
Black	6 (5.9)
Asian	18 (17.8)
Mixed	0 (0)
Other	3 (3)
<b>Smoking status</b>	
Non- smoker	45 (44.6)
Ex- smoker	26 (25.7)
Current smoker	30 (29.7)
<b>Menopausal status</b>	
Pre- menopausal	22 (21.8)
Post- menopausal	79 (78.2)
<b>Parity</b>	
Nulliparous	18 (17.8)
Multiparous	83 (82.2)
<b>Co-morbidities</b>	

<b>Cardiac</b>	
Hypertension	31 (30.7)
Atrial Fibrillation	2 (2)
Heart Failure	3 (3)
Ischaemic heart disease	8 (7.9)
<b>Respiratory</b>	
Asthma	10 (9.9)
COPD	14 (13.9)
<b>Endocrine</b>	
Diabetes Mellitus	12 (11.9)
Hypothyroidism	12 (11.9)
<b>Renal</b>	
Chronic kidney disease	1 (1)
<b>Gynaecological</b>	
Endometriosis	3 (3)
Fibroids	1 (1)
PCOS	2 (2)
<b>Other Previous Malignancy</b>	
Breast	6 (5.9)
Lymphoma	1 (1)
Renal	1 (1)
<b>Presenting Complaint</b>	
<b>Ovarian Cancer symptom<sup>1</sup></b>	
Abdominal/ pelvic pain	61 (60.4)
Abdominal distension	23 (22.8)
Satiety/ loss appetite	3 (3)
Increased urinary urgency/ frequency	4 (4)
<b>Other symptoms related to ovarian cancer<sup>1</sup></b>	
Unexplained weight loss	13 (12.9)
Fatigue	3 (3)
Change in bowel habit	5 (5)
<b>General Gynaecological symptom</b>	
Post-menopausal bleeding	3 (3)
Uro-genital prolapse	1 (1)
Vaginal discharge	1 (1)
Intermenstrual bleeding	3 (3)
Secondary amenorrhoea	2 (2)
Dysmenorrhoea	2 (2)
<b>Other</b>	
Hair loss	1 (1)
Abnormal Blood Glucose	1 (1)
Anaemia	1 (1)
Foot swelling	1 (1)
Rash	1 (1)
<b>Final Diagnosis</b>	
<b>No Pathology</b>	77 (76.2)
<b>Benign Gynae pathology</b>	
Ovarian cyst	10 (9.9)
Endometrial polyp	3 (3)
Atrophy	1 (1)
Hydrosalpinx	1 (1)
Fibroids	2 (2)
Endometriosis	1 (1)
Uro-Genital prolapse	1 (1)
Dysfunctional uterine bleeding	1 (1)
<b>Other</b>	
Adnexal fibrosis	1 (1)
Constipation	1 (1)
Chronic urinary retention	1 (1)
Did not attend investigation	1 (1)
<b>Malignancy</b>	0 (0)

<sup>1</sup> As per the NICE Guidelines (4). IQR- interquartile range. n- number